key: cord-0937218-axordaeo
authors: Shao, Wenxia; Zhang, Weiying; Fang, Xiang; Yu, Daojun; Wang, Xianjun
title: Challenges and countermeasures brought by Omicron Variant
date: 2022-04-26
journal: J Microbiol Immunol Infect
DOI: 10.1016/j.jmii.2022.03.007
sha: 2dd5c5ebe6e122b3d901e02ed192a4cda361734d
doc_id: 937218
cord_uid: axordaeo

The Omicron (B.1.1.529) variant was first reported in South Africa and rapidly spread worldwide in early November 2021. This caused panic in various countries, so it is necessary to understand Omicron Variant. This paper summarizes omicron variant-related research achievements. Studies have shown that Omicron Variant contains many mutations that make it more infectious and transmissible. At the same time, immune escape is also caused, resulting in reduced efficacy of existing vaccines, increased risk of reinfection, treatment failure or reduction of monoclonal antibody therapies, and detection failure. However, current data indicate that Omicron Variant causes mild clinical symptoms and few severe cases and deaths. Omicron Variant is valid for a range of nonpharmaceutical interventions against SARS-COV-2. Improving diagnostic accuracy and enabling timely isolation and treatment of diagnosed cases is also critical to interrupting the spread of omicron variants. COVID-19 vaccine boosters could undoubtedly help control Omicron spread and infection. However, developing a vaccine specific to Omicron Variant is also imminent.

COVID-19, caused by SARS-COV-2 and its various emerging variants, is a severe health threat to humans. 1,2 However, a more worrying issue has recently emerged: a rapid surge of patients is being seen globally. A new SARS-CoV-2 variant makes its way to the world. 3 The WHO named the omicron variant a variant of concern (VOCs) on November 26, 2021. 4 In November 2021, the omicron variant was first found in South Africa. Subsequently, it quickly became the main variant in Gauteng. As of November 15, more than 75% of COVID-19-positive samples detected the omicron J o u r n a l P r e -p r o o f variant in South Africa. 5 By November 29, 2021, cases with omicron variant infection had spread to many other countries. The alarming virus is sweeping the world again.

Overall, more than 60 mutations have been detected in Omicron variants. 6 Among all SARS-CoV-2 variants, Omicron variants had the most mutation sites. In ORF1a, the Omicron variant has six substituents (A2710T, T3255I, K856R, L2084I, I3758 V, and P3395H) and two deletions of a total of four amino acids: amino acids 3674-3676 and amino acid 2083. 7 Previous studies have established that D614G is associated with higher upper respiratory viral load and younger patients. [9] [10] [11] In addition, the mutation of N501Y in the Omicron variant was also detected in alpha, beta, and gamma variants. It can enhance the binding force between spikes and angiotensin-converting enzyme 2, increasing transmission rates. 12 The transmission rate of Omicron variants may be J o u r n a l P r e -p r o o f further enhanced in the presence of concurrent H69/V70 deletions. 13 In addition, Omicron also had P681H and N679K mutations near furin cleavage sites. Binding to basic amino acids around the cleavage site of furin promotes the cleavage of the spikes into S1 and S2, thereby enhancing virus-cell fusion and viral infection. 14 In summary, the Omicron variant possesses the most mutation sites in all SARS-CoV-2 variants identified to date. These mutations are involved in transmissibility, disease severity, and immune escape.

SARS-CoV-2 invades the respiratory system and causes other organ injuries in severe cases, such as kidney injury 15 , liver injury 16 , myocardial injury 17 , coagulation dysfunction 18, and gastrointestinal symptoms. 2, 19 Compared with the early original strains, many clinical studies have suggested that in cases with alpha, beta, and delta variants, the risks of hospitalization, ICU admission, and death were increased. 13, [20] [21] [22] However, the clinical characteristics of the Omicron variant are different.

In Canada, as of December 21, 2021, the KFL&A Region had the highest number of COVID-19 cases compared with any other region, with 1,574 active cases. 23 Of all confirmed or suspected cases of Omicron, 59% were aged between 18 and 24 years, and 27% were aged between 25 and 39 years, while the main outbreak settings were higher education and food and beverage settings. It is worth noting that no cases were hospitalized, and the first modeling estimates placed the Re for Omicron in this region at 1.5. Nasal congestion (73%) was the most common symptom, followed by cough (65%), headache (54%), sore throat (48%), chills (34%), and fever (32%).

Asymptomatic cases accounted for 9.6 percent of the total. Remarkably, shortness of breath occurs in only 10% of cases. Reported confirmed cases with the Omicron variant from South Africa 24,25 and the United States 26,27 were also asymptomatic or had mild symptoms, and no deaths were reported. Subsequently, UKHSA announced that ten individuals infected with Omicron were hospitalized, and one died. 28 As of December 20, 2021, seven deaths in those infected with Omicron have been reported. 29 In conclusion, the virulence of the Omicron variant is weaker than that of other J o u r n a l P r e -p r o o f mutants, and patients are less severe after infection.

The Omicron variant rapidly spreads worldwide. Data from epidemiological surveys show that South Africa has recorded three large outbreaks of COVID-19 transmission since the beginning of 2020. Two of these are caused by beta and delta mutations. Epidemiological data found that the percentage of beta variant infections increased to 50% of the total daily infections in the approximately 100 days since the outbreak. 30 During the same period, the percentage infected with the Delta variant increased to 80%. However, in South Africa, the percentage of Omicron infections reached 90% in approximately 25 days. Early doubling times for Beta, Delta and Omicron variants were 1.7, 1.5 and 1.2 days, respectively. 30 These data suggest that omicron variants may be more infectious than beta and delta variants. It is also worth noting that a recent retrospective study based on population-wide epidemiological data from South Africa suggested a possible increased risk of reinfection with omicrondriven SARS-CoV-2. 31 As a result, the likelihood of COVID-19 spreading in South Africa and even globally in the coming days is high.

In vitro, computational studies applied affinity tests to detect the Delta and Omicron variants and showed that the Omicron variant had a higher affinity for human ACE2 than the Delta variant. The high affinity between the Omicron variant and ACE2 is attributed to its large number of mutations in the SARS-COV-2 receptor-binding domain (RBD). Docking studies showed that mutations of Q493R, N501Y, S371 L, S373P, S375F, Q498R, and T478K were important reasons for high binding affinity with HUMAN ACE2. RBD is a true viral entity that mediates viral entry by recognizing ACE2 receptors. 32, 33 The Omicron variant has 15 mutations in the RBD, while the Delta variant had only the L452R and T478K mutations in the RBD. Among these substitutions, many residues are located near the bound ACE2 receptor. Therefore, these mutations may affect the infectivity and transmissibility of omicron variants. Omicron has a higher proportion of hydrophobic amino acids (such as leucine and phenylalanine) in the whole spike protein and RBD than the Delta type. These amino acids are located J o u r n a l P r e -p r o o f in the core of proteins and are necessary for structural stability. A disordered-ordered transformation was found in Omicron variants in the RBD region of the spike protein (468-473), which may have important implications in the effects of disordered residues/regions on spike protein stability and ACE2 binding. 34 Another interesting finding can partly explain why Omicron Variant's virus spike has a stronger affinity for patients' ACE2. It was found that the positive electrostatic potential showed a clear upward trend from the original virus strain to the Delta virus strain and the recent Omicron variant. Since ACE2 plaques have a negative electrostatic surface potential, it is reasonable to speculate that the higher positive potential of the RBD may increase viral spike orientation and the overall interaction affinity of the ACE2 receptor. The relationship between the increase in positive electrostatic potential and affinity in the Delta VOCs (especially δ B.1.617.2) was discussed. 35 If the electrostatic potential and receptor affinity have a direct relationship, then infectivity exists, then the hypothesis that the transmission of Omicron VOCs is higher than that of other VOCs will be supported. In addition, significant changes in the surface electrostatic potential of Omicron RBD can alter the interaction with macromolecules such as antibodies. 36 In summary, the OM variant has stronger infectivity and transmission power due to more mutations and the surface electrostatic potential in the Omicron RBD.

Alterations in existing COVID-19 infection and vaccine-induced immune protection susceptibility may be associated with mutations in spike proteins. 7, 37, 38 

The sudden emergence of the Omicron variant in South Africa has again increased the risk of SARS-CoV-2 reinfection, suggesting that the Omicron variant may partially evade existing COVID-19 infection and immune responses induced by vaccines. 31 Based on epidemiological data, we know of three outbreaks of COVID-19 in South Africa caused by the original virus, the beta variant, and the delta variant. Unfortunately, the whole country is again shrouded in the shadow of the Omicron variant. 1,20 A preprint J o u r n a l P r e -p r o o f from NCID shows that the rate of new cases in the rapidly developing omicron wave was more than three times that of beta or Delta waves. However, the above data involved people who have already experienced COVID-19. 39 However, it is unexpected that the estimated hazard ratio (HR) for reinfection versus primary infection was lower during the second (Beta) and third waves (Delta) than for the first wave (HR for the There is such a concern that the existing neutralizing activity might be insufficient for adequate immune protection when faced with the Omicron variant. Recently, an in vitro study compared the neutralization of omicron-infected cells in serum samples from participants who received two and three vaccine doses. There were significant differences in geometric mean titers between wild-type, Omicron, and other viruses. 46 These findings, to some degree, can illustrate the hypothesis that the Omicron variant may be more transmissible, so the current vaccination may not be able to provide enough protective effect in preventing infection. 46 In a recent study, geometric mean neutralizing antibody titers (GMTs) were significantly lower in those who received the BNT162b2 vaccine (5.43 and 6.42) of the Omicron variant than in the Beta and Delta variants. GMTs of the two Omicron variants were 35.7 ~ 39.9 times lower than that of the original strain (229.4). There was no significant difference in the GMT value between HKU691 and HKU344-R346K. 47 The additional R346K mutation did not affect neutralization susceptibility, but the Omicron At present, there are still no long-term monitoring data on the effectiveness of currently available COVID-19 vaccines to Omicron spike mutations. Still, we can show that existing vaccines based on wild-type SARS-COV-2 are ineffective enough to prevent mutated infections. 50 Therefore, it is necessary to develop mutation-specific vaccines based on the mutated Spike, especially for the Omicron variant, because vaccines based on the mutated Spike have higher levels of neutralizing antibodies against the mutated virus. In addition, although some vaccines have been developed based on other variants, these vaccine candidates can also be used to prevent Omicron infection and its transmission as long as they contain one or more Omicron mutations.

Notably, Omicron has 15 substitutes in the RBD region, a major target for neutralizing antibodies. In addition, all of these mutations can be located at one or more antigenic J o u r n a l P r e -p r o o f sites of the RBD; including RBS-A, RBS-B, RBS-C, CR302, and S309. 51 Thus, Omicron may be resistant to one or more monoclonal antibodies that target these sites.

In clinical terms, the FDA has approved emergency use of a cocktail of LY-CoV555 (bamlanivimab) and LY-CoV016 (etevimab). According to previous studies, mutations at positions 484 and 417 were associated with immune evasion 52 , and both beta and gamma variants are reported to be resistant to the neutralization of LY-CoV 016 (due to K417N/T) and LY-CoV 555 (due to E484K). 53 

In addition to the influence on antibody efficacy, there is also the risk of detection failure. There is growing evidence that these mutations may reduce the reliability of commercial immunoassays to detect antibodies against SARS-CoV-2. The antigens (spikes or RBD) and epitopes of the prototype SARS-CoV-2 can no longer reflect the sequence of circulating virus variations. As a result, commercially available immunoassays may not be able to identify antibodies triggered by highly mutated SARS-CoV-2 variants. 56 In contrast, mutations in the Omicron strain did not appear to affect the accuracy of the commonly used antigen-based rapid diagnostic test (AG-RDT) test. According to a recent study evaluating ten commercially available COVID-19 antigen tests, there was no significant difference between delta and omicron variants in the analytical sensitivity of the ten antigen kits. 57 All ten kits detected Delta at 6.50 log10 copies/mL (Ct 25.4) and Omicron at 6.39 log10 copies/mL (Ct 25.8), which is consistent with previous studies of assay sensitivity of antigen kits. 57 Neither Delta nor Omicron was detected in any ten kits at the lowest dilution concentrations (5.23 log10 copies/mL, Ct28.8 and J o u r n a l P r e -p r o o f 5.33 log10 copies/mL, Ct 28.8, respectively) . 57 This result is consistent with other work demonstrating the validity of antigen tests for SARS-COV-2 variants. Most Omicron strains also affect the accuracy of conventional PCR detection. However, in RT-PCR, the BA.1 lineage showed S target gene failure (SGTF) due to multiple deletions of the S glycoprotein NTD, while the BA.2 lineage may skip SGTF due to NTD deletion.

In summary, immune escape caused by Omicron Variant causes reduced efficiency of existing vaccines, increased risk of reinfection, treatment failure of monoclonal antibody therapies, and detection failure.

To date, the detailed characteristics of the Omicron variant remain unclear. These mutations can also be observed in other VOCs. Of particular concern is that Omicron may have evolved to spread more easily among humans and resist current antibody therapies. Therefore, there is a definite need to maintain existing public health precautions, including frequent hand washing, physical distancing, and wearing protective equipment. These measures proved effective in preventing the spread of other variants and should also reduce the spread of the Omicron variant. In addition, early diagnosis and timely isolation are essential to reduce the transmission of the virus.

Previous studies have shown that an increase in Omicron infections leads to a higher percentage of PCR tests for spike gene failure. Therefore, it is essential to improve diagnostic accuracy, ensure timely isolation and treatment of infected patients and cut off the cycle of Omicron mutations.

Several studies have reported a decrease in serum neutralizing antibodies six months after vaccination. At the same time, adding a booster can restore the vaccine's effectiveness to its original level, or even higher 57-60 . We believe that additional doses of the COVID-19 vaccine will undoubtedly help prevent the spread of Omicron.

In summary, Omicron Variant contains many mutations that make it more infectious and transmissible. At the same time, immune escape is also caused, resulting in reduced efficacy of existing vaccines, increased risk of reinfection, treatment failure or J o u r n a l P r e -p r o o f reduction of monoclonal antibody therapies, and detection failure. However, current data indicate that Omicron Variant causes mild clinical symptoms and few severe cases and deaths. Omicron Variant is valid for a range of nonpharmaceutical interventions against SARS-COV-2. Improving diagnostic accuracy and enabling timely isolation and treatment of diagnosed cases is also critical to interrupting the spread of omicron variants. Adding additional doses of the COVID-19 vaccine to vaccination schedules will undoubtedly help control the spread and infection of Omicron. However, developing a vaccine against the Omicron variant is also urgent.

Not relevant. We declare that reporting of the study was in line with the Declaration of Helsinki, as revised in 2013.

None declare. Omicron variants contain many mutations that make them more infectious and transmissible. At the same time, immune escape is also caused, resulting in an increased risk of reinfection, reduced efficacy of existing vaccines, treatment failure of monoclonal antibody therapies, and detection failure.

The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape

Cellular Immune Response to COVID-19 and Potential Immune Modulators

Omicron (B.1.1.529) Variant: Development, Dissemination, and Dominance

Classification of omicron (B.1.1.529): SARS-CoV-2 variant of J o u r n a l P r e -p r o o f concern

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

The global epidemic of SARS-CoV-2 variants and their mutational immune escape

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Spike mutation D614G alters SARS-CoV-2 fitness

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Impacts on the structurefunction relationship of SARS-CoV-2 spike by B.1.1.7 mutations

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

A Unique SARS-CoV-2 Spike Protein P681H Variant Detected in Israel

Kidney involvement in COVID-19 and its treatments

Hepatic complications of COVID-19 and its treatment

Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment

Characteristics of coagulation alteration in patients with COVID-19

The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19

South Africa responds to new SARS-CoV-2 variant

SARS-CoV-2 variants of concern are emerging in India

The global epidemic of SARS-CoV-2 variants and their mutational immune escape

Frequently asked questions for the B.1.1.529 mutated SARS-COV-2 lineage in South Africa

Covid-19: South Africa's surge in cases deepens alarm over omicron variant

529)-technical-brief-and-priority-actions-for-member-states. 2021. 27. Omicron Variant: What You Need to Know

Epidemiological update: Omicron variant of concern (VOC) -data as of

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic

Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa

Structure of the SARS-CoV-2 spike receptorbinding domain bound to the ACE2 receptor

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein

617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate

The electrostatic potential of the Omicron variant spike is higher than in Delta and Delta-plus variants: A hint to higher transmissibility

Analysis of COVID-19 vaccines: Types, thoughts, and application

The variants of SARS-CoV-2 and the challenges of vaccines

Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. 2021. 40. Latest updates 12 Dec 2021. on SARS-CoV-2 variants detected in the UK

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron

Estimates of reduced vaccine effectiveness against hospitalization, infection, transmission and symptomatic disease of a new SARS-CoV-2 variant, Omicron (B.1.1.529), using neutralizing antibody titers

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark

Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

Outbreak caused by the SARS-CoV-2 Omicron variant in Norway

Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients

Israeli study finds Pfizer COVID-19 booster protects against Omicron

SARS-CoV-2 Omicron variant: Characteristics and prevention

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies

Comparative genomics and characterization of SARS-CoV-2 P.1 (Gamma) Variant of Concern (VOC) from Amazonas

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

B.1.1.529 escape the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes

Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies

Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated

None declare.